TECH: Ascending Triangle detected on 18 Jun 2026

TECH is forming an ascending triangle with strong technical structure. At $55.00, the stock is consolidating between support at $53.94 and resistance at $56.94. Structure scores 14.0/15 and volume scores 11.5/12, indicating solid pattern integrity. Breakout strength scores 13.0/13, and the overall score of 75.5/98 reflects a high-quality setup. RSI at 58.54 shows neither overbought nor oversold conditions. The pattern suggests an upside breakout target of $57.22, with the stock trading 27.55% above its 52-week low but 23.54% below its 52-week high.

Bio-Techne expanded its spatial biology portfolio in March 2026 with new SPYRE Focus Panels and amplification kits, adding modular panel options and enhanced image-analysis tools. In Q2 fiscal 2026, the company reported $295.9 million in revenue (flat year-over-year) with adjusted EPS of $0.46, while adjusted operating margin expanded 100 basis points to 31.1%. Large pharma end-market delivered the fourth consecutive quarter of double-digit growth. Q3 fiscal 2026 (ended March 31) saw reported revenue decline 2% to $311.4M, but organic revenue grew 3% with spatial biology posting mid-teens growth. Analysts maintain a Moderate Buy rating with price target of $68.58. The stock's 23.79% one-month gain reflects recovery from earlier weakness, with margin expansion and spatial biology momentum offsetting biotech spending headwinds.

A successful breakout above $56.94 resistance would target $57.22 conservatively per measured move calculation, with upside extension possible toward the analyst target zone near $68.58. Volume confirmation is necessary—current volume ratio of 0.85 suggests below-average trade flow, so a breakout should print above 2.75M shares for conviction. The pattern invalidates decisively if the stock closes below support at $53.94, which would suggest weakness below the triangle base. Win probability of 63.6% indicates the setup leans bullish but carries material downside risk if support fails.

Third-quarter earnings showed reported revenue declined 2% year-over-year, negatively impacted by prior-year fast-track orders and timing of large commercial shipments, while biotech spending remained weak. The company operates in cyclical life sciences markets dependent on pharma capital allocation—if emerging biotech spending deteriorates further, organic growth may remain pressured. Volume has been below-average (0.85 ratio), creating thin liquidity for pattern confirmation. A business within the Diagnostics segment is held-for-sale, introducing execution risk around divestiture timing and price. Beta of 0.49 offers downside protection, but sector weakness could still trigger a retest of $53.94 support. No imminent earnings catalyst appears evident from recent data through mid-June 2026.